What are Platform Technologies?
Platform technologies allow improvement of efficacy, safety and convenience of existing pharmaceuticals and can be used to develop novel therapeutics of diseases that are not approachable with existing method of new drug development. Celltrion is exploring various types of platform technologies such as subcutaneous (SC) formulation, ADC, multispecific antibodies and mRNA.
Platform Development Status
As of 2023-
mRNA Platform Technology
mRNA is a molecule that instructs cells to produce copies of specific proteins. The mRNA platform is a synthetically manufactured technology based on mRNA that allows the body to produce, on its own, specific proteins needed to prevent or treat specific diseases. It enables rapid production and is safe because it acts in the cytoplasm, posing no risk of genetic modification.
-
Microbiome Therapeutics
Celltrion is developing microbiome-based Live Biotherapeutic Products (LPBs). By utilizing microorganisms naturally present in the body, these products offer a reduced risk of side effects. Additionally, LPBs can be combined with existing drugs to maximize treatment effectiveness and offer promising treatment alternatives for diseases with limited therapeutic options.
-
New Formulation Development
New formulations are under development to improve drug delivery efficiency and patients' convenience. Celltrion successfully developed the world's first subcutaneous (SC) formulation of infliximab and is continuously developing various types of formulations to expand patient accessibility.
